Plasma A β and PET PiB binding are inversely related in mild cognitive impairment

Neurology

Volumn 77, Issue 2, 2011, Pages 125-131

  Devanand, D P ^a,c   Schupf, N ^b   Stern, Y ^a,b,c   Parsey, R ^a   Pelton, G H ^a   Mehta, P ^c,d   Mayeux, R ^a,b,c  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PITTSBURGH COMPOUND B;

ADULT; AGED; ARTICLE; BRAIN; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; PARAHIPPOCAMPAL GYRUS; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL;

EID: 80051495814     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318224afb7     Document Type: Article

References (38)

1. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994; 17:489-517. (Pubitemid 24117040)
2. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319. (Pubitemid 38269583)
3. Rowe CC, Ng S, Ackermann U, et al. Imaging betaamyloid burden in aging and dementia. Neurology 2007; 68:1718-1725. (Pubitemid 46763260)
4. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PiB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452. (Pubitemid 44214969)
5. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680. (Pubitemid 351294719)
6. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009;1:371-380.
7. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 2008;105:14052-14057.
8. Degerman Gunnarsson M, Lindau M, Wall A, et al. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: an exploratory study. Dement Geriatr Cogn Disord. 2010;29:204-212.
9. Grimmer T, Riemenschneider M, Förstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927-934.
10. Koivunen J, Pirttilä T, Kemppainen N, et al. PET amyloid ligand [11C]PiB uptake and cerebrospinal fluid betaamyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378-383.
11. Lui JK, Laws SM, Li QX, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis 2010;20:1233-1242.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13. Mayeux R, Honig LS, Tang MX, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61:1185-1190. (Pubitemid 37377535)
14. Mehta PD, Pirttilä T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloidβ proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-105. (Pubitemid 30027637)
15. Parsey RV, Sokol LO, Bélanger MJ, et al. Amyloid plaque imaging agent [C-11]-6-OH-BTA-1: biodistribution and radiation dosimetry in baboon. Nucl Med Commun 2005; 26:875-880. (Pubitemid 41426549)
16. Watson CC, Newport D, Casey ME. A single scatter simulation technique for scatter correction in 3D PET. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1996.
17. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I: accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21:1034-1057. (Pubitemid 32823740)
18. Duvernoy H. The Human Brain: Surface, Threedimensional Sectional Anatomy and MRI. New York: Springer-Verlag Wien; 1991.
19. Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PiB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010;23:185-198.
20. Avants B, Klein A, Tustison N, et al. Evaluation of an open-access, automated brain extraction method on multisite multi-disorder data, poster no. 1388. Presented at Human Brain Mapping 2010, Barcelona, Spain, June 2010.
21. Milak MS, DeLorenzo C, Zanderigo F, et al. In vivo quantification of human serotonin 1a receptor using 11CCUMI- 101, an agonist PET radiotracer. J Nucl Med 2010;51:1892-1900.
22. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989;135:309-319. (Pubitemid 19240215)
23. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000;27:661-670.
24. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557-568.
25. van Rossum IA, Vos S, Handels R, et al. Biomarkers as predictors for conversion from mild cognitive impairmentto Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010;20:881-891.
26. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330:1774.
27. Murakami K, Masuda Y, Shirasawa T, et al. The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease. Geriatr Gerontol Int 2010;10(suppl 1): S169-S179.
28. Kuperstein I, Broersen K, Benilova I, et al. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 2010;29: 3408-3420.
29. Ghiso J, Tomidokoro Y, Revesz T, et al. Cerebral amyloid angiopathy and Alzheimer's disease. Hirosaki Igaku 2010; 61(suppl):S111-S124.
30. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519. (Pubitemid 43358072)
31. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease [erratum 2007;64:1246]. Arch Neurol 2007;64: 354-362. (Pubitemid 46425689)
32. van Oijen M, Hofman A, Soares HD, et al. Plasma Aβ (1-40) and Aβ (1-42) and the risk of dementia: a prospective casecohort study. Lancet Neurol 2006;5:655-660. (Pubitemid 44062411)
33. Sundelöf J, Giedraitis V, Irizarry MC, et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population based cohort study. Arch Neurol 2008;65:256-263. (Pubitemid 351240790)
34. Lambert JC, Schraen-Maschke S, Richard F, et al. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 2009;73:847-853.
35. Le Bastard N, Aerts L, Leurs J, et al. No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 2009;55:820-825.
36. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
37. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65:176-183.
38. Cosentino SA, Stern Y, Sokolov E, et al. Plasma β-amyloid and cognitive decline. Arch Neurol Epub 2010 Aug 9.